Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Change in Receivables (2016 - 2025)

Veracyte (VCYT) has disclosed Change in Receivables for 14 consecutive years, with -$3.2 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables fell 58.21% to -$3.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $708000.0 through Dec 2025, down 88.95% year-over-year, with the annual reading at $708000.0 for FY2025, 88.95% down from the prior year.
  • Change in Receivables hit -$3.2 million in Q4 2025 for Veracyte, down from -$425000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $7.1 million in Q1 2025 to a low of -$3.2 million in Q4 2025.
  • Historically, Change in Receivables has averaged $814600.0 across 5 years, with a median of $451000.0 in 2022.
  • Biggest five-year swings in Change in Receivables: surged 1674.79% in 2021 and later crashed 383.72% in 2023.
  • Year by year, Change in Receivables stood at $2.3 million in 2021, then plummeted by 93.92% to $139000.0 in 2022, then surged by 448.92% to $763000.0 in 2023, then crashed by 360.94% to -$2.0 million in 2024, then crashed by 58.21% to -$3.2 million in 2025.
  • Business Quant data shows Change in Receivables for VCYT at -$3.2 million in Q4 2025, -$425000.0 in Q3 2025, and -$2.8 million in Q2 2025.